OSR (NASDAQ:OSRH) Lowered to “Strong Sell” Rating by Wall Street Zen

OSR (NASDAQ:OSRH) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OSR in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

OSR Price Performance

OSR stock opened at $0.54 on Friday. OSR has a fifty-two week low of $0.38 and a fifty-two week high of $1.79. The company’s 50 day simple moving average is $0.48 and its 200 day simple moving average is $0.58. The firm has a market capitalization of $17.72 million, a price-to-earnings ratio of -0.42 and a beta of 0.59.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP bought a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned approximately 0.37% of OSR at the end of the most recent quarter. Institutional investors own 55.30% of the company’s stock.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.